Study of the Safety and Pharmacokinetics of AR-501 (gallium citrate)
Phase: 1/2a
Status: Ongoing
Details
AR-501-001 – A Phase 1/2a randomized, double-blind, two-part, dose-ascending, multicenter study of the safety and pharmacokinetics of AR-501 (gallium citrate), administered via inhalation, in healthy adult and P. aeruginosa infected cystic fibrosis subjects
Sponsor: Aridis
NCT03669614
